Navigation Links
Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management

Collaboration combines insulin expertise of Lilly with Medtronic delivery and glucose sensing leadership

INDIANAPOLIS and MINNEAPOLIS, May 19 /PRNewswire-FirstCall/ -- Two of the most recognized names in diabetes management -Eli Lilly and Company (NYSE: LLY) and Medtronic, Inc. (NYSE: MDT) - today announced a strategic marketing collaboration to bolster each company's commitment to help people with diabetes manage their blood sugar using insulin therapy.

Working collaboratively with health care professionals, Lilly and Medtronic marketing and sales operations in the United States will work to improve the delivery of diabetes education for people and caregivers affected by type 1 diabetes - including the development of new educational resources and classes around the initiation and intensive management of insulin, insulin pump therapy and continuous glucose monitoring (CGM).

The alliance combines the insulin expertise of Lilly - a worldwide leader in diabetes treatment, research and education - with the advanced diabetes technologies of Medtronic, the world's largest manufacturer of insulin pumps and CGM and maker of the world's only integrated diabetes management system that combines the power of insulin pump therapy with CGM.

"Medtronic and Lilly are joining together to help improve patient access to high quality diabetes education," said Chris O'Connell, president of the diabetes business unit and senior vice president at Medtronic. "Because diabetes management is complicated, it is crucial that physicians and patients have the best access to information and educational resources. This collaboration will generate greater awareness and enable more people to benefit from the latest educational tools regarding insulin pump therapy and continuous glucose monitoring."

"People with diabetes have numerous treatment options and devices to help manage blood sugar, but physicians and patients need resources and solutions to integrate these improvements into real-world therapy," said Matt Beebe, diabetes brand leader, Lilly USA, LLC. "With this alliance, Lilly and Medtronic hope to create integrated solutions to address challenges for people taking insulin who need optimal glycemic control. By joining forces, we will help make insulin therapy more achievable by offering new educational materials and resources that help make insulin pump therapy fit into patients' lives."

Both companies are dedicated to improving the overall patient experience and bring trusted reputations along with a history of firsts in diabetes care.

Medtronic has been well-established as the leader in insulin delivery innovation since it introduced the world's first insulin pump in 1983, and has been improving on the technology for more than 25 years. Medtronic continued to innovate with the first CGM system approved for physician use in 1999, the first patient-use CGM in 2003 and the most advanced Web-based therapy management system in 2004. Lilly has long been the leading innovator in insulin therapy; Lilly introduced the world's first insulin for public use in 1923 and has continued to introduce advances in diabetes therapy over the next 85 years.

About Diabetes

According to the Centers for Disease Control and Prevention, diabetes affects nearly 24 million Americans; of that, nearly one-quarter, or nearly six million people, do not know they have the disease.(1) Diabetes is the sixth leading cause of death in the United States and costs approximately $174 billion per year in direct and indirect medical expenses.(1,2)

About the Diabetes Business at Medtronic

The Diabetes business at Medtronic ( is the world leader in advanced diabetes management solutions, including integrated diabetes management systems, insulin pump therapy, continuous glucose monitoring systems and therapy management software.

About Medtronic

Medtronic, Inc. (, headquartered in Minneapolis, is the global leader in medical technology, alleviating pain, restoring health and extending life for millions of people around the world.

About Lilly Diabetes

For more than 85 years, Lilly has been a worldwide leader in pioneering industry-leading solutions to support people living with and treating diabetes. Lilly introduced the world's first commercial insulin in 1923, and remains at the forefront of medical and delivery device innovation to manage diabetes. Lilly is also committed to providing solutions beyond therapy -- practical tools, education and support programs to help overcome barriers to success along the diabetes journey. At Lilly, the journey of each person living with or treating diabetes inspires ours. For more information, visit

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at

(1) Centers for Disease Control and Prevention (CDC). National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Rev ed. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2008

(2) American Diabetes Association. Direct and indirect costs of diabetes in the United States. Available at: Accessed January 16, 2009


(Logo: )

(Logo: )

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
4. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
5. Lillys CEO Calls for Reform of Nations Drug Safety System
6. Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
7. Lilly Grant to VA Will Enhance Services for Returning Combat Veterans
8. Lilly Delivers Strong Third-Quarter Results
9. Lilly and MacroGenics Announce Licensing and Collaboration Agreement
10. Eli Lilly and Company Aids California Recovery Effort
11. Eli Lilly and Company Announces 2007 Lilly Reintegration Awards Recipients
Post Your Comments:
(Date:11/25/2015)... ... 25, 2015 , ... In an ongoing Clinical Study conducted by an independent ... UV Angel is evaluating the efficacy of its product and its disinfection protocol. This ... beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical center ...
(Date:11/25/2015)... ... November 25, 2015 , ... "When I underwent breast reconstruction ... incredibly uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my ... RECOVERY BRA for added comfort and support. The bra is easier to put ...
(Date:11/25/2015)... ... ... Since its launch in 2012, the Regenestem brand ( ... to patients with chronic degenerative medical conditions. Now, the U.S. Patent and Trademark ... Organizations are required to hold a registered trademark in order to make licensing ...
(Date:11/24/2015)... ... ... Dr. Todd S. Afferica, a noted general dentist in Norcross, GA ... Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in many of his dental procedures. ... traditional cutting tools, such as the scalpel and high-speed drill, which can both cause ...
(Date:11/24/2015)... ... , ... In an article published November 12th by Obesity News ... or are not eligible for bariatric surgery. The article explains that candidates for weight ... 100 pounds overweight, or have a BMI of 35 and over with at least ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015 --> ... "Spine Biologics Market by Product Type (Bone Graft, Bine Graft ... and Fusion, Posterior Lumbar Interbody Fusion), End User, and Geography ... market was valued at $1.90 Billion in 2014 and is ... of 4.4% during the forecast period of 2015 to 2020. ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical Devices ... pleased to announce the appointment of Anders Jonzon ... Dr. Jonzon is ... at Children,s Hospital, Uppsala University, Uppsala and Children,s Hospital, ... he was a fellow at the Cardiovascular Institute (UCSF). ...
(Date:11/24/2015)... 2015 . ... adds Latest Guidebook for Chinese Medical Device GMP ... in November 2015 to the medical devices market ... at . China ... global economies with a fifth population in the ...
Breaking Medicine Technology: